Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • dupilumab
Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity
Posted inClinical Updates Wellness & Lifestyle

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

Posted by By MedXY 07/31/2025
Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.
Read More
  • Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial
  • Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials
  • Comparative Analysis of Virtual Reality Therapies for Psychotic Symptoms: Auditory Hallucinations vs. Persecutory Delusions
  • Distinct Genomic Mutation Patterns in Early-Onset Colorectal Cancer: Implications for Clinical Stratification and Precision Medicine
  • First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer clinical trial clinical trials diabetes diagnosis diet epidemiology exercise FDA FDA approval GLP-1 health healthcare Hypertension immunotherapy lifestyle lifestyle intervention longevity maternal health men's health Menopause mental health nutrition obesity older adults PCOS Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep stroke treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top